-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Transmission electron microscope image of hepatitis virus particles
.
Source: CDC/ EH Cook, Jr.
: In a new paper published in the journal Nature, scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, describe the structure of key proteins on the surface of the hepatitis C virus (HCV).
), and how it interacts with receptors found on some human cells
.
This discovery provides new clues for the development of hepatitis C vaccine
The hepatitis C virus is usually spread through blood, for example during childbirth or when sharing drug injection equipment
.
Since the hepatitis C virus may not cause any symptoms for several years after the initial infection, the infection is often undetected
In a new paper published in the journal Nature, researchers from NIAID and other organizations describe proteins expressed on the surface of HCV (called HCV E2) and receptors found on the surface of certain human cells (called HCV E2).
It is called CD81)
.
Previous studies have shown that antibodies interfere with the interaction between these two proteins
The researchers determined the exact structure of HCV E2 and CD81, and studied the interaction of these two proteins when exposed to each other under different conditions
.
They found that under acidic conditions, HCV E2 easily binds to the CD81 receptor
The researchers say that the way in which these structures and their interactions are identified may lay the foundation for the development of an anti-HCV vaccine
.
A vaccine may cause a person to produce specific antibodies that prevent HCV E2 from binding to CD81 and prevent the virus from entering the cell, thereby preventing HCV infection
A Kumar et al.
10.
